Propofol
intravenous medication used in anaesthesia
Propofol is the active component of an intravenous anesthetic used for induction and maintenance of general anesthesia. Propofol was first marketed under the brand name Diprivan. Intravenous administration is used to induce unconsciousness, after which anesthesia may be maintained using a combination of medications. Propofol is manufactured as part of a sterile injectable emulsion using soybean oil and lecithin, which gives it a white milky color.
Compared to other anesthetics, recovery from propofol-induced anesthesia is generally quick and infrequently associated with such side effects as drowsiness, nausea, vomiting. Propofol may be used before diagnostic procedures requiring anesthesia, in the management of refractory status epilepticus, and for induction or maintenance of anesthesia before and during surgery. It may be administered as a bolus or an infusion, or as a combination of the two.
First synthesized in 1973 by John B. Glen, a British veterinary anesthesiologist working for Imperial Chemical Industries (ICI, later AstraZeneca), propofol was introduced for therapeutic use as a lipid emulsion in the United Kingdom and New Zealand in 1986. Propofol (Diprivan) received FDA approval in October 1989. It is on the World Health Organization's List of Essential Medicines.
The public source identifies “Propofol” as intravenous medication used in anaesthesia. This brief keeps that definition visible, then builds a research path around Propofol, intravenous and medication.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Propofol”, the useful work is to connect “intravenous medication used in anaesthesia” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Sep 21, 2026. The linked authority identifier is Q422740. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1973, 1986 and 1989.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Propofol”, its source revision and the description used here.
- Expand the search: follow Propofol primary sources, Propofol archive and Propofol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Propofol”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Propofol” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.